Carri Geer, Ph.D., is the Vice President of Pharmaceutical Development and leads the drug substance, drug product, device and analytical development for Novan’s drug candidates. Additionally, Dr. Geer serves as the technical liaison for collaborative partnerships. Dr. Geer has approximately 10 years of experience in pharmaceutical product development with a background in analytical and bioanalytical chemistry. During her tenure at Novan, Dr. Geer has been responsible for establishing and growing the analytical capabilities of the Company. Prior to joining Novan, Dr. Geer was employed at Merck and bridged the interface between R&D and cGMP analytical testing.
Jeff N. Hunter, MS, is the EVP and Chief Business Officer and has been integral to the company’s execution and operational success since its inception. With more than 35 years of broad business experience including as co-founder and former CEO and Chairman of a small-cap public company, Mr. Hunter has built Novan’s manufacturing and corporate infrastructure as well as strengthened supply chain and business relationships. His versatility and in-depth understanding of the company’s business includes the role of corporate secretary. In 2013, the Triangle Business Journal recognized Mr. Hunter as a top executive in his field. In 2015, he was appointed to serve on the Board of Directors of the North Carolina Biotechnology Center.
Tomoko Maeda-Chubachi, MD, PhD, MBA, is the Vice President of Medical Dermatology and provides medical input to help drive the strategy, design and execution of Novan's development programs. Most recently, she served as senior medical director at GSK, leading clinical development projects for psoriasis, atopic dermatitis, pemphigus and androgenic alopecia. Prior to GSK, she held clinical and medical affairs roles at Eli Lilly and Company and Pfizer, Inc. Dr. Maeda-Chubachi was an academic physician and dermatologist for ten years before entering the pharmaceutical industry.
G. Kelly Martin is Chief Executive Officer of Novan, Inc. He served as CEO of Elan, Ireland’s largest indigenous biotech company, from February 2003 until its successful $8.6 Billion sale to Perrigo Company in December 2013. Before joining Elan, Mr. Martin spent more than 20 years at Merrill Lynch & Co., Inc., where he held a broad array of operating and executive responsibilities. Mr. Martin also serves as a non-executive director on a number of public and private company boards and is a co-founder and director of Brandon Point Industries.
Elizabeth Messersmith, Ph.D is the Senior Vice President of Clinical Operations and is responsible for the direction and execution of the Company’s broad and diverse clinical drug development programs. Most recently, Dr. Messersmith held the position of Senior Vice President, Clinical Operations and Data Management at from Quark Pharmaceuticals, Inc. Prior to Quark, she served in research and development operations and clinical operations roles for Balance Therapeutics, Inc. and previous to that, she was at Elan Pharmaceuticals. Dr. Messersmith has a B.A. and M.A. from the University of Kansas in Human Biology and Physiology, respectively, and a Ph.D. in Biomedical Science from the University of Texas Health Science at Houston.
Andrew Novak is the Vice President, Chief Accounting Officer and leads the accounting and financial reporting functions at Novan. Mr. Novak has spent a majority of his accounting career in the life science industry and has significant depth and breadth of experience directing financial and regulatory reporting for public companies. Prior to joining Novan in 2016, Mr. Novak served the as Director, Financial and SEC Reporting at Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company developing anti-infective therapies, from 2014 to 2016. Before joining Scynexis, Mr. Novak was a Financial Audit Manager at Deloitte and a Technical Manager at the AICPA. Mr. Novak received a M.S. in Accounting and a B.S. in Business Administration and Finance from the University of North Carolina at Wilmington and is a Certified Public Accountant.
Tim O’Sullivan, JD, MBA, is the Vice President of Intellectual Capital and spearheads the strategic development of Novan’s intellectual property portfolio. He manages Novan’s licensing strategy and is responsible for building the Company’s robust barriers to entry. Mr. O’Sullivan has more than 20 years of experience in developing intellectual property portfolios. Before joining Novan, Mr. O’Sullivan was the director of intellectual property and business development for LED Lighting Solutions at Cree, Inc.
Paula Brown Stafford, MPH, is the Chief Development Officer and leads the tactical execution of clinical trials and the establishment of statistics and data management functions for Novan. Prior to joining Novan, she served as president of clinical development at Quintiles (now QuintilesIMS), where she was responsible for all Phase I-IV clinical development operations globally, reaching $3 billion in annual revenue. In addition to her role at Novan, Ms. Stafford continues to participate in other professional activities, including serving as a director at Health Decisions, Inc. and adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at The University of North Carolina at Chapel Hill, and also maintains her third-party consulting business. She was named as one of the 10 top women in biotech by FierceBiotech in 2012, recognized as a Distinguished Alumna at UNC Chapel Hill in 2016, and recently designated an NACD Governance Fellow. She holds a Bachelor of Science and a Masters in Public Health, both from The University of North Carolina at Chapel Hill, with her specialization in Biostatistics.
Nathan Stasko, PhD, is co-founder, President and Chief Scientific Officer and a Director of Novan, Inc. Dr. Stasko has led the transformation of the Company’s nitric oxide platform from the academic benchtop to Phase 3 clinical trials and is considered a leading expert in the field of nitric oxide. He is an inventor of the core Novan technology and of more than 100 patent filings, 19 of which have issued, and has authored several peer-reviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide. Dr. Stasko has led the Company through each of its private financings totaling more than $100 million, as well as the award of government grants and contracts totaling $15 million, the latter ultimately resulting in Novan’s national recognition as a Tibbetts Award winner for excellence in Small Business Innovation Research. He has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise, who share his vision to position Novan as a commercially successful leader in the dermatology market.